

Crystallization and preliminary X-ray crystallographic analysis of the Hsp100 chaperone ClpB from *Thermus thermophilus*

Sukyeong Lee,^a Makyio Hisayoshi,^b Masasuke Yoshida^b and Francis T. F. Tsai^{a*}

^aVerna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA, and

^bChemical Resources Laboratory, Tokyo Institute of Technology, Yokohama 226-8503, Japan

Correspondence e-mail: ftsai@bcm.tmc.edu

ClpB from *Thermus thermophilus* (TClpB) has been crystallized by the vapour-diffusion method in the presence of adenosine 5'-(β,γ -imido)triphosphate (AMPPNP) and adenosine 5'-(γ -thio)triphosphate (ATP γ S), respectively. Complete native data sets have been collected from frozen crystals, which belonged to the primitive orthorhombic space group $P2_12_12_1$ with unit-cell parameters $a = 109.2$, $b = 139.6$, $c = 213.0$ Å, $\alpha = \beta = \gamma = 90^\circ$.

Received 7 October 2003

Accepted 15 October 2003

1. Introduction

Bacterial ClpB and its yeast orthologue heat-shock protein 104 (Hsp104) are ATP-dependent molecular chaperones which form large ring structures and belong to the Clp/Hsp100 family of ATPases associated with diverse cellular activities (AAA⁺; Schirmer *et al.*, 1996; Neuwald *et al.*, 1999; Vale, 2000; Ogura & Wilkinson, 2001). In principle, two classes of Clp/Hsp100 proteins can be distinguished: class 1 proteins such as ClpA, ClpB/Hsp104 and ClpC consist of two distinct but conserved Walker-type nucleotide-binding domains (NBD), while class 2 proteins such as bacterial ClpX and ClpY (HslU) contain only a single NBD that is sufficient for function (Schirmer *et al.*, 1996). Unlike other class 1 proteins, however, members of the ClpB/Hsp104 family have a longer middle region or 'linker' that separates the two NBDs. This ClpB/Hsp104-linker is essential for chaperone activity (Cashikar *et al.*, 2002), but its precise structure and function is only poorly understood owing to the lack of a high-resolution crystal structure. Moreover, unlike other Clp/Hsp100 proteins, ClpB/Hsp104 does not associate with the structurally and functionally unrelated ClpP protease and does not direct the proteolytic degradation of its substrate proteins (Gottesman *et al.*, 1997; Horwich *et al.*, 1999; Wickner *et al.*, 1999; Dougan *et al.*, 2002). ClpB/Hsp104 rather functions exclusively as a molecular chaperone by facilitating the disaggregation of stress-damaged proteins (Sanchez & Lindquist, 1990; Sanchez *et al.*, 1992; Parsell *et al.*, 1994; Mogk *et al.*, 1999). The full recovery of these proteins requires the assistance of the cognate DnaK/Hsp70 chaperone system (Glover & Lindquist, 1998; Goloubinoff *et al.*, 1999; Mogk *et al.*, 1999; Motohashi *et al.*, 1999; Zolkiewski, 1999).

Currently, little is known about the structure–function relationship of ClpB/Hsp104

molecular chaperones. The crystal structure of an isolated N-terminal domain and that of NBD1 of *Escherichia coli* ClpB (Li & Sha, 2002, 2003) have been determined recently. While these structures have provided the first insight into this remarkable molecular machine, the structure of the full-length protein and of its functional assembly remain elusive. To understand the structural basis for protein disaggregation, we have crystallized full-length TClpB in complex with AMPPNP and ATP γ S, respectively.

2. Experimental

2.1. Expression, purification and crystallization of TClpB

E. coli BL21 (DE3) cells were transformed with an expression plasmid (pMCB1) containing the *clpB* gene under control of the T7 RNA polymerase promoter (Motohashi *et al.*, 1999). Cells were grown at 310 K to mid-log phase in Luria–Bertani medium and induced by the addition of 1 mM isopropyl- β -D-thiogalactopyranoside (IPTG). The cells were grown for a further 3 h after induction and harvested by low-speed centrifugation at 277 K. For purification, the cell pellet was disrupted by passing through a microfluidizer processor (Microfluidics Corporation). TClpB was purified from the supernatant by several column-chromatography steps in the following order: DEAE-Sepharose (BioRad), butyl-Sepharose (Tosohaas) and Mono-Q (Amersham Biosciences). After this process, the protein was judged to be greater than 98% pure by sodium dodecyl sulfate gel electrophoresis (data not shown). The purified protein was aliquoted and stored at 193 K.

Prior to crystallization, the protein was chromatographed on a Superose-6 size-exclusion column (Amersham Biosciences) to isolate the TClpB hexamer and was concen-

trated to 15 mg ml⁻¹ in 10 mM Tris-HCl pH 7.6, 100 mM NaCl, 10 mM MgCl₂ and 5% glycerol. The protein concentration was estimated by measuring the absorption at 280 nm in 6.0 M guanidine-HCl, 20 mM potassium phosphate buffer at pH 6.5 using a molar extinction coefficient of 57 180 M⁻¹ cm⁻¹ calculated by the method of Gill and von Hippel (1989). For crystallization, 5 mM AMPPNP or ATP γ S were added directly to the protein sample. Native crystals (Fig. 1) were obtained at 291 K using the hanging-drop vapour-diffusion method by mixing 2 μ l of protein sample with an equal volume of well solution consisting of 4–5% (w/v) polyethylene glycol 4000, 200 mM sodium acetate pH 4.1–4.3, 200 mM KCl and 20% glycerol. Crystals appeared after two to three weeks and reached maximum dimensions of 0.04 \times 0.08 \times 0.3 mm after two to three months.

2.2. X-ray crystallographic analysis of the crystals

Crystals were harvested into stabilizing solution consisting of 6% (w/v) polyethylene glycol 4000, 200 mM sodium acetate pH 4.1–4.3, 200 mM KCl and 20% glycerol and were transferred into a cryoprotectant solution consisting of stabilizing solution with a final glycerol concentration of 25%. The crystals were suspended in small nylon loops at the end of Hampton mounting pins (Hampton Research) and flash-frozen by plunging into liquid nitrogen.

Data were processed and scaled using the *HKL* software package (Otwinowski & Minor, 1997) and analyzed using *CNS* (Brünger *et al.*, 1998) and the *CCP4* suite of programs (Collaborative Computational Project, Number 4, 1994).




Figure 1
Crystals of full-length TC1pB in complex with AMPPNP.

3. Results and discussion

A number of different crystal forms were obtained, which all diffracted poorly (data not shown). After extensive screening of potential crystallization conditions, we obtained crystal forms of TC1pB (Fig. 1) which diffracted to 3.2 Å (AMPPNP) and 3.6 Å resolution (ATP γ S), respectively, using synchrotron radiation (Table 1).

Table 1
Statistics of the native data sets for TC1pB.

Values in parentheses are for the highest resolution shell.

Type	Native	Native
Space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁
Source	NLSL X25	NLSL X25
Wavelength (Å)	1.10	1.10
Detector type	B4 CCD 2K \times 2K Brandeis	Quantum 4 ADSC
Resolution (Å)	48.8–3.2 (3.3–3.2)	49.2–3.6 (3.7–3.6)
Unit-cell parameters (Å)		
<i>a</i>	109.2	109.2
<i>b</i>	139.6	139.0
<i>c</i>	213.0	210.5
Ligand	AMPPNP	ATP γ S
No. reflections	215099	279835
No. unique reflections	52294	37661
Data completeness (%)	95.9 (70.4)	99.9 (100)
<i>I</i> / σ (<i>I</i>)	27.7	12.5
<i>R</i> _{sym} † (%)	3.6 (27.5)	4.5 (41.4)

† $R_{\text{sym}} = \sum_{hkl} |I(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} I(hkl)$, where $\langle I(hkl) \rangle$ is the mean of the symmetry-equivalent reflections of $I(hkl)$.




Figure 2
Stereographic projection of the self-rotation function with $\kappa = 60^\circ$. The self-rotation function is contoured at the 1 σ level with a 1 σ cutoff. The resolution of the data used was 8–4 Å, with a radius of integration of 30 Å.

axis coincides with the crystallographic twofold screw axis, giving rise to a helical assembly with three molecules in the asymmetric unit. The presence of three molecules in the asymmetric unit would result in a V_M of $2.8 \text{ \AA}^3 \text{ Da}^{-1}$, corresponding to a solvent content of 55%, which is near the median of the commonly observed values of V_M (Matthews, 1968).

We thank Dr Y. Watanabe, Dr M. E. Sowa and J.-M. Choi for useful discussions, Dr T. Kawashima for help with data collection and the staff of NSLS X25 (Drs M. Becker, L. Berman and R. Sweet), APS-SBC 19ID (Dr A. Joachimiak) and MacCHESS (Dr D. Thiel) for access to and help with their respective synchrotron X-ray sources. SL acknowledges initial support by the Howard Hughes Medical Institute. FTFT is supported by a Scientist Development Grant from the American Heart Association (0130124N), a grant from the Robert A. Welch Foundation (Q-1530) and a grant from the Gillson Longenbaugh Foundation.

References

- Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T. & Warren, G. L. (1998). *Acta Cryst.* **D54**, 905–921.
- Cashikar, A. G., Schirmer, E. C., Hattendorf, D. A., Glover, J. R., Ramakrishnan, M. S., Ware, D. M. & Lindquist, S. L. (2002). *Mol. Cell*, **9**, 751–760.
- Collaborative Computational Project, Number 4 (1994). *Acta Cryst.* **D50**, 760–763.
- Dougan, D. A., Mogk, A. & Bukau, B. (2002). *Cell. Mol. Life Sci.* **59**, 1607–1616.
- Gill, S. C. & von Hippel, P. H. (1989). *Anal. Biochem.* **182**, 319–326.
- Glover, J. R. & Lindquist, S. (1998). *Cell*, **94**, 73–82.
- Goloubinoff, P., Mogk, A., Zvi, A. P., Tomoyasu, T. & Bukau, B. (1999). *Proc. Natl Acad. Sci. USA*, **96**, 13732–13737.
- Gottesman, S., Wickner, S. & Maurizi, M. R. (1997). *Genes Dev.* **11**, 815–823.
- Horwich, A. L., Weber-Ban, E. U. & Finley, D. (1999). *Proc. Natl Acad. Sci. USA*, **96**, 11033–11040.
- Li, J. & Sha, B. (2002). *J. Mol. Biol.* **318**, 1127–1137.
- Li, J. & Sha, B. (2003). *Structure*, **11**, 323–328.
- Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
- Mogk, A., Tomoyasu, T., Goloubinoff, P., Rüdiger, S., Röder, D., Langen, H. & Bukau, B. (1999). *EMBO J.* **18**, 6934–6949.
- Motohashi, K., Watanabe, Y., Yohda, M. & Yoshida, M. (1999). *Proc. Natl Acad. Sci. USA*, **96**, 7184–7189.
- Neuwald, A. F., Aravind, L., Spouge, J. L. & Koonin, E. V. (1999). *Genome Res.* **9**, 27–43.
- Ogura, T. & Wilkinson, A. J. (2001). *Genes Cells*, **6**, 575–597.
- Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.
- Parsell, D. A., Kowal, A. S., Singer, M. A. & Lindquist, S. (1994). *Nature (London)*, **372**, 475–478.
- Sanchez, Y. & Lindquist, S. (1990). *Science*, **248**, 1112–1115.
- Sanchez, Y., Taulien, J., Borkovich, K. A. & Lindquist, S. (1992). *EMBO J.* **11**, 2357–2364.
- Schirmer, E. C., Glover, J. R., Singer, M. A. & Lindquist, S. (1996). *Trends Biochem. Sci.* **21**, 289–296.
- Tong, L. & Rossmann, M. G. (1990). *Acta Cryst.* **A46**, 783–792.
- Vale, R. D. (2000). *J. Cell Biol.* **150**, F13–F19.
- Wickner, S., Maurizi, M. R. & Gottesman, S. (1999). *Science*, **286**, 1888–1893.
- Zolkiewski, M. (1999). *J. Biol. Chem.* **274**, 28083–28086.